Literature DB >> 7690738

Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma.

M Toi1, J Kashitani, T Tominaga.   

Abstract

Clinical importance of tumor angiogenesis, especially its significance as a prognostic indicator, was examined in 125 primary breast-cancer patients. The grade of neovascularization was assessed by the vessel density which was obtained by immunocytochemical staining for factor VIII antigen. Post-operative survey demonstrated that the vessel density is a statistically significant predictor of relapse-free survival (median follow-up period: 62 months). Patients with over 100 counts of factor-VIII antigen-positive cells per 200 x field in the most active areas of neovascularization showed significantly poorer prognosis than those with less than 100 counts. The prognostic value of the vessel density was also confirmed by another evaluation method using immunocytochemical staining to CD-31 which is a platelet/endothelial cell adhesion molecule. A significant difference in relapse-free survival rate was shown between patients having higher counts of CD-31 positive cells and those having lower counts. Breakdown analysis stratified by nodal status showed that the vessel density was a significant prognostic indicator in node-negative and node-positive patients. Multivariate analysis indicated that the vessel density is an independent prognostic indicator in primary breast-cancer patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690738     DOI: 10.1002/ijc.2910550305

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  59 in total

1.  Fully automated microvessel counting and hot spot selection by image processing of whole tumour sections in invasive breast cancer.

Authors:  J A Beliën; S Somi; J S de Jong; P J van Diest; J P Baak
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

2.  Morphometric study of tumor angiogenesis as a new prognostic factor in nasopharyngeal carcinoma patients.

Authors:  L Rubio; J S Burgos; C Morera; F J Vera-Sempere
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

3.  Angiogenesis Inhibitor O-(Chloroacetyl-carbamoyl) fumagillol (TNP-470) Inhibits Tumor Angiogenesis, Growth and Spontaneous Metastasis of MKL-4 Human Breast Cancer Cells in Female Athymic Nude Mice.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

4.  Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth.

Authors:  P Lin; P Polverini; M Dewhirst; S Shan; P S Rao; K Peters
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

5.  Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin's gastric lymphoma patients.

Authors:  Alexander Darom; Ilias P Gomatos; Emmanuel Leandros; Emmu Chatzigianni; Dimitris Panousopoulos; Manousos M Konstadoulakis; George Androulakis
Journal:  World J Gastroenterol       Date:  2006-03-28       Impact factor: 5.742

6.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

7.  Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations.

Authors:  Y Yao; L Jin; A Fuchs; A Joseph; H M Hastings; I D Goldberg; E M Rosen
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

Review 8.  Intratumor microvessel density as a prognostic factor in cancer.

Authors:  N Weidner
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

9.  Tumor angiogenesis in advanced stage ovarian carcinoma.

Authors:  H C Hollingsworth; E C Kohn; S M Steinberg; M L Rothenberg; M J Merino
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

Review 10.  UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction.

Authors:  Fumihiro Tanaka
Journal:  Surg Today       Date:  2007-10-25       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.